Listen to this page using ReadSpeaker

ARVO 2018: Dr. Shannon Boye Reports on her Emerging Gene Therapy for LCA (GUCY2D)

At the annual ARVO research conference in Honolulu, I had an opportunity to talk with FFB-funded researcher Shannon Boye, PhD, University of Florida, about her advancement of gene therapy for Leber congenital amaurosis (GUCY2D mutations) toward a clinical trial.


2 Responses to 'ARVO 2018: Dr. Shannon Boye Reports on her Emerging Gene Therapy for LCA (GUCY2D)'

  1. Marie Kyser says:

    I am so excited about your research. Both of my kids have RP. They both have had genetic testing. My son (Seth Kyser) has LCA and was a candidate for the clinical trial in Washington State several years ago. At the last minute, he was rejected due to one gene or something did not match the parameters. We were devastated. If you have any lists for information about your research or any research opportunities, please add us to your list. Seth is good with facebook etc., he sent me this article so however we can keep up with any advances would be appreciated. Phone 334-324-9690 Address 1025 Peace Church Road Wetumpka, AL 36093

Leave a Reply

Your email address will not be published. Required fields are marked *

*